Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 MAB, in Combination with Ibrutinib Achieves 95% ORR in Patients with High-Risk Relapsed/Refractory CLL.

Drug Category: Array
Conference Category: Array
Lead Author: Burke J, et al.
Published Date: 20/06/2015
Download Link: /wp-content/uploads/2019/03/UTX%20IB%20Lugano%20Slide%20Deck%20FINAL.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top